報價延遲最少15分鐘:2025/06/02 18:37 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.87/-0.95
|
|
企業價值
61.16M
|
| 資產負債 |
|
每股賬面淨值
2.45
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.16M
|
|
每股收益
0.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 18:37 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncologyproduct candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595. |